Literature DB >> 27966092

Attitudes of Patients and Relatives Toward Disability and Treatment in Malignant MCA Infarction.

Hermann Neugebauer1,2, Matthias Schnabl3, Dorothée Lulé4, Peter U Heuschmann5,6, Eric Jüttler4,7.   

Abstract

BACKGROUND: Attitudes among patients and relatives toward the degree of acceptable disability and the importance of aphasia are critical in deciding on decompressive hemicraniectomy (DHC) in malignant middle cerebral artery infarction (MMI). However, most MMI patients are not able to communicate their will. Furthermore, attitudes of healthy individuals and relatives may not correspond to those of stroke patients.
METHODS: This is a multicenter survey among 355 patients and 199 relatives during treatment for acute minor or moderate severe ischemic stroke in Germany. Questions address the acceptance of disability, importance of aphasia, and the preferred treatment in the hypothetical case of future MMI.
RESULTS: mRS scores of 2 or better were considered acceptable by the majority of all respondents (72.9-88.1%). A mRS of 3, 4, and 5 was considered acceptable by 56.0, 24.5, and 6.8%, respectively. Except for a mRS of 1, relatives indicated each grade of disability significantly more often acceptable than patients. Differences regarding acceptable disability and treatment decision were depending on family status, housing situation, need of care, and disability. The presence of aphasia was considered important for treatment decision by both patients (46.5%) and relatives (39.2%). Older respondents more often refrained from DHC (p < 0.001).
CONCLUSION: In Germany, there is substantial heterogeneity in patients and relatives regarding acceptable disability, aphasia, and treatment decision in the hypothetical case of MMI. Relatives significantly overestimate the degree of disability that is acceptable to stroke patients. Further studies are warranted to determine whether differences in attitudes impact on the decision to undergo DHC.

Entities:  

Keywords:  Decompressive hemicraniectomy; Disability; Malignant middle cerebral artery infarction; Outcome

Mesh:

Year:  2017        PMID: 27966092     DOI: 10.1007/s12028-016-0362-7

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  35 in total

1.  Letter by Woodworth and Simard Regarding Article, "Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction: Ethical Considerations".

Authors:  Graeme Woodworth; J Marc Simard
Journal:  Stroke       Date:  2015-10-06       Impact factor: 7.914

2.  Response to Letter Regarding Article, "Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction: Ethical Considerations".

Authors:  Stephen Honeybul; Kwok Ming Ho; Grant Gillett
Journal:  Stroke       Date:  2015-10-06       Impact factor: 7.914

3.  Outcome Following Decompressive Hemicraniectomy for Malignant Cerebral Infarction: Ethical Considerations.

Authors:  Stephen Honeybul; Kwok Ming Ho; Grant Gillett
Journal:  Stroke       Date:  2015-08-04       Impact factor: 7.914

4.  [Prognosis and quality of life after decompressive hemicraniectomy: a nationwide survey in Germany on the attitudes held by doctors and nurses].

Authors:  S Schwarz; C Kühner
Journal:  Nervenarzt       Date:  2012-06       Impact factor: 1.214

5.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

6.  The disability paradox: high quality of life against all odds.

Authors:  G L Albrecht; P J Devlieger
Journal:  Soc Sci Med       Date:  1999-04       Impact factor: 4.634

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Long-term survival with unfavourable outcome: a qualitative and ethical analysis.

Authors:  Stephen Honeybul; Grant R Gillett; Kwok M Ho; Courtney Janzen; Kate Kruger
Journal:  J Med Ethics       Date:  2014-06-25       Impact factor: 2.903

9.  Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial.

Authors:  Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke
Journal:  Stroke       Date:  2007-08-09       Impact factor: 7.914

10.  A survey on self-assessed well-being in a cohort of chronic locked-in syndrome patients: happy majority, miserable minority.

Authors:  Marie-Aurélie Bruno; Jan L Bernheim; Didier Ledoux; Frédéric Pellas; Athena Demertzi; Steven Laureys
Journal:  BMJ Open       Date:  2011-02-23       Impact factor: 2.692

View more
  5 in total

1.  Infarct volume predicts outcome after decompressive hemicraniectomy for malignant hemispheric stroke.

Authors:  Nils Hecht; Hermann Neugebauer; Ingo Fiss; Alexandra Pinczolits; Peter Vajkoczy; Eric Jüttler; Johannes Woitzik
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-30       Impact factor: 6.200

2.  Prognostication in Acute Neurological Emergencies.

Authors:  Kelly L Sloane; Julie J Miller; Amanda Piquet; Brian L Edlow; Eric S Rosenthal; Aneesh B Singhal
Journal:  J Stroke Cerebrovasc Dis       Date:  2022-01-07       Impact factor: 2.136

3.  Twitter Journal Club Impact on Engagement Metrics of the Neurocritical Care Journal.

Authors:  Aarti Sarwal; Masoom Desai; Pallavi Juneja; Joni K Evans; Abhay Kumar; Eelco Wijdicks
Journal:  Neurocrit Care       Date:  2022-03-02       Impact factor: 3.532

4.  Attitudes of Nurses Toward Disability and Treatment in Space-Occupying Middle Cerebral Artery Stroke.

Authors:  Hermann Neugebauer; Flora Malakou; Ingo Uttner; Melitta Köpke; Eric Jüttler
Journal:  Neurocrit Care       Date:  2019-02       Impact factor: 3.210

5.  A study of the opinions of Swedish healthcare personnel regarding acceptable outcome following decompressive hemicraniectomy for ischaemic stroke.

Authors:  Magnus Olivecrona; Stephen Honeybul
Journal:  Acta Neurochir (Wien)       Date:  2017-11-04       Impact factor: 2.216

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.